JP2020007367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020007367A5 JP2020007367A5 JP2019172314A JP2019172314A JP2020007367A5 JP 2020007367 A5 JP2020007367 A5 JP 2020007367A5 JP 2019172314 A JP2019172314 A JP 2019172314A JP 2019172314 A JP2019172314 A JP 2019172314A JP 2020007367 A5 JP2020007367 A5 JP 2020007367A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- liposome
- cytarabine
- daunorubicin
- liposomes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 22
- 239000002502 liposome Substances 0.000 claims 19
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 8
- 229960000684 cytarabine Drugs 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 7
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 7
- 229960000975 daunorubicin Drugs 0.000 claims 7
- 238000004108 freeze drying Methods 0.000 claims 5
- 239000002577 cryoprotective agent Substances 0.000 claims 3
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 2
- 101001000212 Rattus norvegicus Decorin Proteins 0.000 claims 2
- 239000012736 aqueous medium Substances 0.000 claims 2
- FVJZSBGHRPJMMA-UHFFFAOYSA-N distearoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000009477 glass transition Effects 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Claims (14)
- 凍結乾燥ゲル相リポソーム組成物であって、当該組成物は、
（ａ）ゲル相リポソーム、ここで、該リポソームの膜は、７：２：１のＤＳＰＣ：ＤＳＰＧ：ＣＨＯＬを成分として含み、かつ、該リポソームは一定比率のダウノルビシンとシタラビンと安定に会合している；及び、
（ｂ）該リポソームの外側に存在する凍結保護物質
を含み、
ここで、該リポソームが実質的に内側の凍結保護物質を含有しない、組成物。 - ダウノルビシン：シタラビンの一定の比率が１：５である、請求項１に記載の組成物。
- 前記組成物が薬学的担体中に再構成される場合、前記リポソームの平均直径が、凍結乾燥前の該組成物と比較して維持され、かつ、ダウノルビシンとシタラビンが実質的にリポソーム内に保持される、請求項１又は請求項２に記載の組成物。
- 前記組成物が再構成される場合、前記ダウノルビシン：シタラビンの比率が、凍結乾燥前の該組成物と比較して２５％以下変化する、請求項１又は請求項２に記載の組成物。
- 前記リポソームの平均直径が、凍結乾燥前に測定された該値と比較して、前記リポソーム組成物の凍結乾燥後および再構成の際、２５％以下増加する、請求項１又は請求項２に記載の組成物。
- 前記平均直径が、５℃〜２５℃の保存で少なくとも６ヶ月間維持される、請求項５に記載の組成物。
- 前記リポソーム組成物が再構成の際、ダウのルビシン及びシタラビンのそれぞれの少なくとも７５％が維持される、請求項１又は請求項２に記載の組成物。
- 平均直径が、５℃〜２５℃の保存で少なくとも６ヶ月間維持される、請求項７に記載の組成物。
- 前記リポソームのサイズ分布が、前記リポソーム組成物の凍結乾燥後および再構成の際、２５％以下変化する、請求項１又は請求項２に記載の組成物。
- 請求項１に記載の組成物を調製する方法であって、ゲル相リポソームを含む水性媒体を外部の保護物質の存在下で凍結乾燥に付すことを含み、
ここで、前記リポソームは該リポソームの膜は、７：２：１のＤＳＰＣ：ＤＳＰＧ：ＣＨＯＬを成分として含み；かつ、一定の比率のダウノルビシンとシタラビンが該リポソームと安定に会合しており；かつ、実質的に内側の凍結保護物質を含有しない、方法。 - ゲル相リポソームを含む前記水性媒体が、前記媒体のガラス転移温度（Ｔｇ）未満である温度で凍結される、請求項１０に記載の方法。
- 被験者にダウノルビシンとシタラビンを投与するための薬学的組成物を調製する方法であって、薬学的担体中で請求項１〜請求項８のいずれか１項に記載されたリポソーム組成物を再構成して再構成された組成物を得ることを含む、方法。
- 動物にダウノルビシンとシタラビンを投与する方法において使用するための請求項１２に記載の方法により調製された組成物。
- 動物の癌を治療する方法において使用するための請求項１２に記載の方法により調製された組成物。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021196626A JP7476161B2 (ja) | 2011-10-21 | 2021-12-03 | 凍結乾燥リポソーム |
| JP2024000732A JP2024045183A (ja) | 2011-10-21 | 2024-01-05 | 凍結乾燥リポソーム |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161550047P | 2011-10-21 | 2011-10-21 | |
| US61/550,047 | 2011-10-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018095127A Division JP6592556B2 (ja) | 2011-10-21 | 2018-05-17 | 凍結乾燥リポソーム |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021196626A Division JP7476161B2 (ja) | 2011-10-21 | 2021-12-03 | 凍結乾燥リポソーム |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020007367A JP2020007367A (ja) | 2020-01-16 |
| JP2020007367A5 true JP2020007367A5 (ja) | 2020-02-27 |
Family
ID=48141268
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537142A Active JP6133308B2 (ja) | 2011-10-21 | 2012-10-15 | 凍結乾燥リポソーム |
| JP2017074348A Active JP6359717B2 (ja) | 2011-10-21 | 2017-04-04 | 凍結乾燥リポソーム |
| JP2018095127A Active JP6592556B2 (ja) | 2011-10-21 | 2018-05-17 | 凍結乾燥リポソーム |
| JP2019172314A Pending JP2020007367A (ja) | 2011-10-21 | 2019-09-20 | 凍結乾燥リポソーム |
| JP2021196626A Active JP7476161B2 (ja) | 2011-10-21 | 2021-12-03 | 凍結乾燥リポソーム |
| JP2024000732A Pending JP2024045183A (ja) | 2011-10-21 | 2024-01-05 | 凍結乾燥リポソーム |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537142A Active JP6133308B2 (ja) | 2011-10-21 | 2012-10-15 | 凍結乾燥リポソーム |
| JP2017074348A Active JP6359717B2 (ja) | 2011-10-21 | 2017-04-04 | 凍結乾燥リポソーム |
| JP2018095127A Active JP6592556B2 (ja) | 2011-10-21 | 2018-05-17 | 凍結乾燥リポソーム |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021196626A Active JP7476161B2 (ja) | 2011-10-21 | 2021-12-03 | 凍結乾燥リポソーム |
| JP2024000732A Pending JP2024045183A (ja) | 2011-10-21 | 2024-01-05 | 凍結乾燥リポソーム |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US10028912B2 (ja) |
| EP (2) | EP3572071A1 (ja) |
| JP (6) | JP6133308B2 (ja) |
| KR (5) | KR102284689B1 (ja) |
| CN (2) | CN108853031A (ja) |
| AU (1) | AU2012326370C9 (ja) |
| BR (1) | BR112014009305B1 (ja) |
| CA (1) | CA2852777C (ja) |
| DK (1) | DK2768484T3 (ja) |
| ES (1) | ES2750368T3 (ja) |
| FR (1) | FR19C1063I2 (ja) |
| HR (1) | HRP20191683T1 (ja) |
| HU (2) | HUE045978T2 (ja) |
| IL (1) | IL232161B (ja) |
| LU (1) | LUC00135I2 (ja) |
| NL (1) | NL301016I2 (ja) |
| NO (1) | NO2019041I1 (ja) |
| PL (1) | PL2768484T3 (ja) |
| PT (1) | PT2768484T (ja) |
| RU (1) | RU2648753C2 (ja) |
| SI (1) | SI2768484T1 (ja) |
| WO (1) | WO2013059133A1 (ja) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102284689B1 (ko) * | 2011-10-21 | 2021-08-02 | 셀라토 파마슈티칼즈, 인코포레이티드 | 동결건조된 리포좀 |
| CN105555301B (zh) | 2013-08-13 | 2021-04-16 | 西北大学 | 肽缀合颗粒 |
| US11471401B2 (en) | 2014-08-28 | 2022-10-18 | The General Hospital Corporation | Injectable slurries and methods of manufacturing the same |
| PL3185854T3 (pl) | 2014-08-28 | 2022-01-31 | The General Hospital Corporation | Zawiesiny do wstrzykiwań oraz sposoby ich wytwarzania i stosowania |
| US11504322B2 (en) | 2014-08-28 | 2022-11-22 | The General Hospital Corporation | Injectable slurries and methods of manufacturing the same |
| US11298318B2 (en) * | 2015-04-13 | 2022-04-12 | Fountain Technologies International, Llc | One-step method for production of ultra-small lipid structures |
| KR102716928B1 (ko) | 2015-07-22 | 2024-10-11 | 닛토덴코 가부시키가이샤 | 나노 입자 동결건조물 형태를 위한 조성물 및 방법 |
| HK1258724A1 (zh) | 2015-11-11 | 2019-11-15 | Celator Pharmaceuticals, Inc. | 选择白血病对象的治疗方案的分析和方法 |
| CN109069288B (zh) | 2016-02-26 | 2022-04-19 | 通用医疗公司 | 医用冰浆生产和递送系统和方法 |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US20200230057A1 (en) * | 2017-07-10 | 2020-07-23 | Immunovaccine Technologies Inc. | Pharmaceutical Compositions, Methods for Preparation using Lipid Vesicle Particles of Defined Size, and Uses Thereof |
| WO2020068979A1 (en) | 2018-09-25 | 2020-04-02 | Celator Pharmaceuticals, Inc. | Low-intensity treatment of hematological disorders |
| US11400065B2 (en) | 2019-03-01 | 2022-08-02 | Flamel Ireland Limited | Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state |
| WO2020264161A1 (en) * | 2019-06-28 | 2020-12-30 | Donald Picker | Method of reconstituting liposomal annamycin |
| JP2022542571A (ja) * | 2019-07-24 | 2022-10-05 | ザ ジェネラル ホスピタル コーポレイション | カプセル化により異なる凝固点を有する物質を作製する方法 |
| US11980636B2 (en) | 2020-11-18 | 2024-05-14 | Jazz Pharmaceuticals Ireland Limited | Treatment of hematological disorders |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| CN115252563B (zh) * | 2022-06-24 | 2024-07-12 | 石药集团中奇制药技术（石家庄）有限公司 | 一种柔红霉素阿糖胞苷脂质体冻干品的制备方法 |
| CN116003493B (zh) * | 2022-12-16 | 2025-02-28 | 常州金远药业制造有限公司 | 一种二价铜离子及阿糖胞苷的回收方法 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880635B1 (en) * | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
| US5077056A (en) | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| JPS62501631A (ja) * | 1985-01-11 | 1987-07-02 | ザ・リ−ジェンツ・オブ・ジ・ユニバ−シィティ・オブ・カリフォルニア | リポソ−ムの保持法 |
| CA1256372A (en) | 1985-04-11 | 1989-06-27 | Koichiro Miyazima | Process for producing liposome composition |
| US4927571A (en) | 1987-05-18 | 1990-05-22 | Liposome Technology, Inc. | Preparation of injectable doxorubicin/liposome suspension |
| US4915951A (en) | 1987-12-03 | 1990-04-10 | California Institute Of Technology | Cryoprotective reagent |
| JP2792702B2 (ja) * | 1988-10-05 | 1998-09-03 | ネクスター・フアーマシユーテイカルズ・インコーポレイテツド | 乾燥時に改善された安定性を示すリポソームの調製方法 |
| US5049392A (en) * | 1989-01-18 | 1991-09-17 | The Liposome Company, Inc. | Osmotically dependent vesicles |
| CA2246778A1 (en) * | 1996-02-19 | 1997-08-21 | Per Helge Gulliksen | Thermally stabilized contrast agent |
| IT1289938B1 (it) * | 1997-02-20 | 1998-10-19 | Angelini Ricerche Spa | Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e |
| GB9813100D0 (en) | 1998-06-18 | 1998-08-19 | Secr Defence | Method of forming liposomes |
| JP2003504389A (ja) | 1999-07-16 | 2003-02-04 | アルザ・コーポレーション | 凍結／融解ダメージに耐性を有するリポソーム組成物 |
| US6984395B2 (en) * | 2001-04-11 | 2006-01-10 | Qlt, Inc. | Drug delivery system for hydrophobic drugs |
| JP4822666B2 (ja) | 2001-10-03 | 2011-11-24 | セレーター ファーマシューティカルズ インコーポレイテッド | 金属イオンをローディングするリポソーム |
| US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| US20050118249A1 (en) | 2001-11-13 | 2005-06-02 | Murray Webb | Lipid carrier compositions and methods for improved drug retention |
| US20050118250A1 (en) * | 2001-11-13 | 2005-06-02 | Paul Tardi | Lipid carrier compositions with enhanced blood stability |
| US7179484B2 (en) | 2002-11-06 | 2007-02-20 | Azaya Therapeutics, Inc. | Protein-stabilized liposomal formulations of pharmaceutical agents |
| JP2006522026A (ja) * | 2003-04-02 | 2006-09-28 | セレーター ファーマスーティカルズ、インク． | カンプトセシンとフルオロピリミジンとを組み合わせた組成物 |
| PT1744764E (pt) * | 2004-04-22 | 2012-08-30 | Celator Pharmaceuticals Inc | Formulações lipossómicas de agentes antraciclina e análogos de citidina |
| US7893338B2 (en) * | 2004-07-15 | 2011-02-22 | Creative Technology Ltd | Method of composing music on a handheld device |
| EP1809254A2 (en) * | 2004-10-28 | 2007-07-25 | Alza Corporation | Lyophilized liposome formulations and method |
| JP4990786B2 (ja) * | 2004-11-05 | 2012-08-01 | イネックス ファーマシューティカルズ コーポレイション | 薬物リポソーム製剤を安定化するための組成物および方法 |
| WO2006055903A1 (en) | 2004-11-18 | 2006-05-26 | Celator Pharmaceuticals, Inc. | Method for loading multiple agents into delivery vehicles |
| JP5687411B2 (ja) | 2005-10-25 | 2015-03-18 | セレーター ファーマスーティカルズ、インク． | 固形腫瘍のための定率配合薬の治療 |
| US20090148506A1 (en) | 2005-12-22 | 2009-06-11 | Awa Dicko | Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof |
| AU2008216083B2 (en) * | 2007-02-16 | 2014-02-06 | Jazz Pharmaceuticals Therapeutics, Inc. | Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders |
| WO2009097011A1 (en) | 2007-08-17 | 2009-08-06 | Celator Pharmaceuticals, Inc. | Improved platinum drug formulations |
| CN101878024B (zh) | 2007-11-28 | 2014-04-09 | 塞拉特药物股份有限公司 | 改良的紫杉烷递送系统 |
| ES2704986T3 (es) | 2008-10-16 | 2019-03-21 | Celator Pharmaceuticals Inc | Combinaciones de una camptotecina liposomal soluble en agua con cetuximab o bevacizumab |
| PL2508170T3 (pl) | 2009-12-03 | 2015-12-31 | Jiangsu Hengrui Medicine Co | Liposom zawierający irynotekan lub jego chlorowodorek i metoda jego otrzymywania |
| EP2531175A2 (en) * | 2010-02-01 | 2012-12-12 | Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. | Liposomes comprising amphipathic drugs and method for their preparation |
| KR102284689B1 (ko) * | 2011-10-21 | 2021-08-02 | 셀라토 파마슈티칼즈, 인코포레이티드 | 동결건조된 리포좀 |
-
2012
- 2012-10-15 KR KR1020207013990A patent/KR102284689B1/ko active Active
- 2012-10-15 ES ES12841616T patent/ES2750368T3/es active Active
- 2012-10-15 EP EP19183846.5A patent/EP3572071A1/en active Pending
- 2012-10-15 US US14/352,662 patent/US10028912B2/en active Active
- 2012-10-15 RU RU2014120475A patent/RU2648753C2/ru active
- 2012-10-15 BR BR112014009305-9A patent/BR112014009305B1/pt active IP Right Grant
- 2012-10-15 HR HRP20191683 patent/HRP20191683T1/hr unknown
- 2012-10-15 CA CA2852777A patent/CA2852777C/en active Active
- 2012-10-15 HU HUE12841616A patent/HUE045978T2/hu unknown
- 2012-10-15 CN CN201810733439.3A patent/CN108853031A/zh active Pending
- 2012-10-15 KR KR1020197027220A patent/KR102113753B1/ko active Active
- 2012-10-15 CN CN201280059606.1A patent/CN104114156A/zh active Pending
- 2012-10-15 AU AU2012326370A patent/AU2012326370C9/en active Active
- 2012-10-15 JP JP2014537142A patent/JP6133308B2/ja active Active
- 2012-10-15 KR KR1020227034406A patent/KR20220141906A/ko not_active Ceased
- 2012-10-15 KR KR1020217023773A patent/KR102452305B1/ko active Active
- 2012-10-15 EP EP12841616.1A patent/EP2768484B1/en not_active Revoked
- 2012-10-15 DK DK12841616.1T patent/DK2768484T3/da active
- 2012-10-15 SI SI201231668T patent/SI2768484T1/sl unknown
- 2012-10-15 PT PT128416161T patent/PT2768484T/pt unknown
- 2012-10-15 PL PL12841616T patent/PL2768484T3/pl unknown
- 2012-10-15 WO PCT/US2012/060293 patent/WO2013059133A1/en not_active Ceased
- 2012-10-15 KR KR1020147012039A patent/KR102024836B1/ko active Active
-
2014
- 2014-04-22 IL IL232161A patent/IL232161B/en active IP Right Grant
-
2017
- 2017-04-04 JP JP2017074348A patent/JP6359717B2/ja active Active
-
2018
- 2018-02-07 US US15/891,170 patent/US10166184B2/en active Active
- 2018-05-17 JP JP2018095127A patent/JP6592556B2/ja active Active
- 2018-11-05 US US16/181,203 patent/US10835492B2/en active Active
-
2019
- 2019-09-20 JP JP2019172314A patent/JP2020007367A/ja active Pending
- 2019-10-10 HU HUS1900047 patent/HUS1900047I1/hu unknown
- 2019-10-23 FR FR19C1063C patent/FR19C1063I2/fr active Active
- 2019-10-24 LU LU00135C patent/LUC00135I2/fr unknown
- 2019-10-25 NL NL301016C patent/NL301016I2/nl unknown
- 2019-11-25 NO NO2019041C patent/NO2019041I1/no unknown
-
2020
- 2020-11-13 US US17/097,530 patent/US20210169803A1/en not_active Abandoned
-
2021
- 2021-12-03 JP JP2021196626A patent/JP7476161B2/ja active Active
-
2022
- 2022-07-13 US US17/812,414 patent/US20230172855A1/en active Pending
-
2024
- 2024-01-05 JP JP2024000732A patent/JP2024045183A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024045183A5 (ja) | ||
| JP2014532623A5 (ja) | ||
| RU2014120475A (ru) | Лиофилизированные липосомы | |
| Wu et al. | Inhibition of tumor metastasis by liquid‐nitrogen‐shocked tumor cells with oncolytic viruses infection | |
| ES2662916T3 (es) | Materiales compuestos que contienen tabaco | |
| AU2023214307B2 (en) | High surface-area lyophilized compositions comprising arsenic for oral administration in patients | |
| WO2019023564A8 (en) | High concentration anti-c5 antibody formulations | |
| JP2013511557A5 (ja) | ||
| JP2013177473A (ja) | 凍結乾燥フォームによる生物活性材料の防腐 | |
| CN103041399B (zh) | 一种耐热保护剂及其应用 | |
| WO2018041261A1 (zh) | 一种肿瘤治疗药物 | |
| CN104983591A (zh) | 一种双重修饰β-胡萝卜素脂质体及其制备方法 | |
| Lingen et al. | The promoting effect of lycopene on the non-specific resistance of animals | |
| JP2013544288A5 (ja) | ||
| Chen et al. | A biomimetic phototherapeutic nanoagent based on bacterial double-layered membrane vesicles for comprehensive treatment of oral squamous cell carcinoma | |
| PE20160536A1 (es) | FORMULACION INMUNOGENICA QUE CONTIENE BCG VIVAS RECOMBINANTES QUE EXPRESAN ANTIGENOS DE METAPNEUMOVIRUS (hMPV), EN UNA SUSPENSION QUE SE PREPARA A PARTIR DE UN LIOFILIZADO SIN LA NECESIDAD DE UN ADYUVANTE | |
| JP2015526463A5 (ja) | ||
| CA3173740A1 (en) | Method of long-term preservation of chemical and biological species using sugar glasses | |
| CN112972366A (zh) | 一种可注射光热化疗增敏载药水凝胶及其制备方法 | |
| CN104814943A (zh) | 一种载盐酸阿霉素交联透明质酸复合膜的制备方法 | |
| JP2016132664A (ja) | Ｌ‐アスコルビン酸配合凍結乾燥化粧料 | |
| Gotohda et al. | Combination of active and passive immunization and chemotherapy to transplantation of methylcholanthrene-induced tumor in WKA rats | |
| JPWO2023136329A5 (ja) | ||
| US20210402006A1 (en) | Nanoparticles and uses thereof | |
| CN108261545A (zh) | 一种光敏剂冻干组合物及其制备方法 |